Title: K(v) 7 (KCNQ) channel openers normalize central 2-deoxyglucose uptake in a mouse model of mania and increase prefrontal cortical and hippocampal serine-9 phosphorylation levels of GSK3β.
Journal: Journal of neurochemistry 20120501
Title: The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.
Journal: Basic & clinical pharmacology & toxicology 20111101
Title: Kv7 (KCNQ) channel openers induce hypothermia in the mouse.
Journal: Neuroscience letters 20110120
Title: Differential effects of ICA-27243 on cloned K(V)7 channels.
Journal: Pharmacology 20100101
Title: The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Journal: Neuroscience letters 20091113
Title: Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania.
Journal: Behavioural brain research 20090317
Title: In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models.
Journal: The Journal of pharmacology and experimental therapeutics 20080901
Title: N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Journal: Molecular pharmacology 20080301
Title: Wickenden AD, et al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol. 2008 Mar;73(3):977-86.
Title: Amato G, et al. N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. ACS Med Chem Lett. 2011 Mar 31;2(6):481-4.
